SCHEMBL6776397

SCHEMBL6776397

CCc1ccc(-c2nc(Cc3ccc(/C=C/CSCC(=O)OC)o3)c(C)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
POLB P06746 4/20 0.49
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
HSD17B10 Q99714 4/20 0.44
KDM4E B2RXH2 4/20 0.43
RAB9A P51151 1/20 0.43
HPGD P15428 3/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TSHR P16473 1/20 0.41
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776403 1.00 MAPT (0.49) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6780462 0.92 SMN1; SMN2 (0.46) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6780459 0.92 SMN1; SMN2 (0.46) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6776165 0.90 KDM4E (0.45) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6776171 0.90 KDM4E (0.45) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6773453 0.90 KDM4E (0.49) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6773460 0.90 KDM4E (0.49) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6771328 0.89 HSD17B10 (0.41) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6771330 0.89 HSD17B10 (0.41) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL6775329 0.84 HSD17B10 (0.38) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US claimed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US claimed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP claimed
US-6821994-B2 A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATOR, AN OXAZOL-4-YL-METHYLFURAN-2-YL-2-PROPENYLTHIO- OR SULFONYL- OR SULFINYL-ACETIC ACID OR METHYL ESTER ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-23 US disclosed
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US disclosed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US disclosed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD MAPT 3767/4885SMN1; SMN2 4662/4885POLB 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.